Literature DB >> 10073605

Angiotensin II receptor type 1 gene expression in human glomerulonephritis and diabetes mellitus.

J Wagner1, F Gehlen, A Ciechanowicz, E Ritz.   

Abstract

The renin-angiotensin system plays an important role in the progression of chronic renal disease. Although the expression of renin and angiotensin-converting enzyme in experimental and human renal disease has been well characterized, no information is available regarding human angiotensin type 1 (AT1) receptor expression. The net effect of renin depends on AT1 receptor expression, among other factors. Receptor expression was determined in renal biopsy samples (including all tissue components) and isolated glomeruli from patients with glomerulonephritis (GN) or diabetic nephropathy (non-insulin-dependent diabetes mellitus). Biopsy samples and isolated glomeruli from tumor-free tissue from tumor nephrectomies served as controls. Human AT1 receptor gene expression was determined by quantitative reverse transcription-PCR, using an AT1 receptor deletion mutant as the internal standard. In whole biopsy samples from 37 patients with various types of GN, AT1 receptor mRNA levels were lower, compared with nine control biopsy samples (P < 0.001). AT1 receptor mRNA levels were also significantly lower (P < 0.001) in eight samples from patients with diabetic nephropathy. In microdissected glomeruli, AT1 receptor gene expression was significantly lower in samples from patients (n = 22) with various types of GN, compared with 12 microdissected tumor nephrectomy control samples (P < 0.0023). It is concluded that AT1 receptor mRNA expression is low in glomeruli of patients with chronic renal disease. This may reflect a regulatory response to (inappropriately) high intrarenal angiotensin II concentrations.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10073605     DOI: 10.1681/ASN.V103545

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  9 in total

Review 1.  Chronic kidney disease and albuminuria in arterial hypertension.

Authors:  Giovanna Leoncini; Francesca Viazzi; Roberto Pontremoli
Journal:  Curr Hypertens Rep       Date:  2010-10       Impact factor: 5.369

Review 2.  Pathogenesis of IgA nephropathy.

Authors:  Kar Neng Lai
Journal:  Nat Rev Nephrol       Date:  2012-03-20       Impact factor: 28.314

3.  Enhanced hemodynamic responses to angiotensin II in diabetes are associated with increased expression and activity of AT1 receptors in the afferent arteriole.

Authors:  Jie Zhang; Helena Y Qu; Jiangping Song; Jin Wei; Shan Jiang; Lei Wang; Liqing Wang; Jacentha Buggs; Ruisheng Liu
Journal:  Physiol Genomics       Date:  2017-08-25       Impact factor: 3.107

4.  Retinoic acid receptor alpha and retinoid X receptor specific agonists reduce renal injury in established chronic glomerulonephritis of the rat.

Authors:  Matthias Schaier; Sabine Liebler; Kerstin Schade; Fujio Shimizu; Hiroshi Kawachi; Hermann-Joseph Grone; Roshantha Chandraratna; Eberhard Ritz; Juergen Wagner
Journal:  J Mol Med (Berl)       Date:  2004-01-08       Impact factor: 4.599

Review 5.  Involvement of glomerular renin-angiotensin system (RAS) activation in the development and progression of glomerular injury.

Authors:  Shoji Kagami
Journal:  Clin Exp Nephrol       Date:  2011-12-02       Impact factor: 2.801

6.  ACE2 deficiency increases NADPH-mediated oxidative stress in the kidney.

Authors:  Jan Wysocki; David I Ortiz-Melo; Natalie K Mattocks; Katherine Xu; Jessica Prescott; Karla Evora; Minghao Ye; Matthew A Sparks; Syed K Haque; Daniel Batlle; Susan B Gurley
Journal:  Physiol Rep       Date:  2014-03-24

Review 7.  Antihypertensive treatment and renal protection: the role of drugs inhibiting the renin-angiotensin-aldosterone system.

Authors:  Francesca Viazzi; Giovanna Leoncini; Roberto Pontremoli
Journal:  High Blood Press Cardiovasc Prev       Date:  2013-10-04

8.  Angiotensin II type 1 receptor blockers favorably affect renal angiotensin II and MAS receptor expression in patients with diabetic nephropathy.

Authors:  Ye-Ping Ma; Yue Yang; Shi-Min Jiang; Lin Liu; Zheng Zhang; Yi-Ning Wang; Gu-Ming Zou; Wen-Ge Li
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2020 Apr-Jun       Impact factor: 1.636

9.  The Treatment Effectiveness Evaluation for Slowing the Progression of Diabetic Nephropathy During Stage 4 Chronic Kidney Disease.

Authors:  Tianyu Yu; Shimin Jiang; Yue Yang; Jinying Fang; Guming Zou; Hongmei Gao; Li Zhuo; Wenge Li
Journal:  Diabetes Ther       Date:  2020-11-29       Impact factor: 2.945

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.